Medical weight management | New York
Foundayo is the brand name for orforglipron, an FDA-approved once-daily oral GLP-1 receptor agonist. It is used with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity or adults with overweight and at least one weight-related condition. It can be taken with or without food. Lilly announced its U.S. launch in April 2026.
Foundayo is FDA approved and commercially launched in the United States. Its initial prescribing information was revised in April 2026. This page describes evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The label is for adults with obesity or adults with overweight and at least one weight-related comorbid condition. It is not labeled as a diabetes medicine, for pediatric weight treatment, or for use together with another GLP-1 receptor agonist.
The clinician should confirm the adult weight-management indication, treatment history, current medicines, and diabetes and eye history. The review also covers gastrointestinal or gallbladder concerns, kidney and liver context, pregnancy and procedure plans, and personal or family history relevant to the boxed warning.
Foundayo is swallowed whole once daily, with or without food. The current label starts at 0.8 mg daily and increases in stages at intervals of at least 30 days according to response and tolerability, up to a labeled maximum of 17.2 mg daily.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, symptoms of pancreatitis or gallbladder disease, blood glucose when relevant, eye history in diabetes, interacting oral medicines, and pregnancy prevention counseling.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The clinician should confirm the adult weight-management indication, treatment history, current medicines, and diabetes and eye history. The review also covers gastrointestinal or gallbladder concerns, kidney and liver context, pregnancy and procedure plans, and personal or family history relevant to the boxed warning.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, symptoms of pancreatitis or gallbladder disease, blood glucose when relevant, eye history in diabetes, interacting oral medicines, and pregnancy prevention counseling.
Nao Medical must confirm adult candidacy, interaction review, contraception counseling, dose-escalation support, pharmacy and payer workflow, adverse-effect triage, and follow-up before offering this pathway.
Foundayo has important interaction details that differ from peptide GLP-1 medicines, including CYP3A4 and OATP1B considerations, a simvastatin limit, and possible effects on oral medicine absorption. It also requires added contraception counseling after initiation and each dose increase for patients using oral contraceptives.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
The clinician reviews weight history, prior treatment, current medicines, related conditions, pregnancy plans when relevant, and the patient's goals.
The visit addresses label criteria, contraindications, interactions, side effects, nutrition, activity, and whether another treatment path is more appropriate.
If a prescription is appropriate, the team discusses the dosage form, administration instructions, coverage process, and follow-up. Approval and supply are not guaranteed.
Follow-up considers response, tolerability, adherence, dose changes, related conditions, and whether treatment should continue or change.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Explore Nao Medical's broader weight-management program and treatment options.
Compare the label and administration of a different daily oral GLP-1 product.
Review the weekly injection and broader Wegovy questions.
Review a weekly GIP and GLP-1 medicine with a distinct label.
Coordinate glucose-lowering medicines when diabetes is part of the clinical picture.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
FDA-approved identity, indication, dose escalation, contraindications, interactions, and safety information.
Open official sourceApproval context and exact product identity.
Open official sourceOfficial commercial launch date and U.S. access context.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371